3,4-dihydroxybenzoate

structure in first source

Networked: 5 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Phenols: 677
        Hydroxybenzoates: 18
        3,4-dihydroxybenzoate: 5
        Benzoates: 426
        Hydroxybenzoates: 18
        3,4-dihydroxybenzoate: 5
- Carboxylic Acids: 973
  - Hydroxy Acids: 94
    - Hydroxybenzoates: 18
      - 3,4-dihydroxybenzoate: 5
  - Carbocyclic Acids
    - Benzoates: 426
      - Hydroxybenzoates: 18
        3,4-dihydroxybenzoate: 5

Experts

1.	Bondeva, Tzvetanka: 1 article (01/2016)
2.	Claus, Ralf A: 1 article (01/2016)
3.	Franke, Sybille: 1 article (01/2016)
4.	Schindler, Claudia: 1 article (01/2016)
5.	Schindler, Katrin: 1 article (01/2016)
6.	Wolf, Gunter: 1 article (01/2016)
7.	Andersen, Julie K: 1 article (02/2014)
8.	Chinta, Shankar J: 1 article (02/2014)
9.	Rajagopalan, Subramanian: 1 article (02/2014)
10.	Ercan, Altan: 1 article (04/2005)

Related Diseases

1.	Ischemia 05/01/2000 - "Compared to the nonischemic striatum, the ratio of the hydroxylation product 3,4-dihydroxybenzoate (34DHB) to 4HB (trapping agent) in the ipsilateral striatum increased significantly 30 min after ischemia induction. " 11/01/1995 - "Reperfused hearts receiving N-acetylcysteine since the last 5 min of ischemia had also a four-times lower 3,4-dihydroxybenzoate release, but their coronary flow rate response was similar to that of untreated hearts. " 11/01/1995 - "The capacity of N-acetylcysteine to directly scavenge hydroxyl radical produced by rat hearts reperfused after 90 min of low-flow ischemia was assessed by the hydroxylation of 4-hydroxybenzoate into 3,4-dihydroxybenzoate using a gas chromatography-mass spectrometric assay. " 11/01/1995 - "Compared to untreated hearts: reperfused hearts treated with N-acetylcysteine from the start of ischemia (i) released four times less 3,4-dihydroxybenzoate, but similar amounts of lactate dehydrogenase or glutathione, (ii) showed a nitric oxide-dependent increase in coronary flow rate, and (iii) contained less oxidized glutathione, but similar amounts of reduced glutathione. "
2.	Mitochondrial Diseases (Mitochondrial Disease) 02/01/2014 - "Pharmacological prolyl hydroxylase domain inhibition via 3,4-dihydroxybenzoate was found to significantly attenuate hallmark mitochondrial dysfunction and loss of dopaminergic substantia nigral pars compacta neurons associated with this model. "
3.	Sepsis (Septicemia) 01/01/2016 - "Pharmacological inhibition of PHDs, leading to HIF activation, was achieved by intraperitoneal application of 3,4-dihydroxybenzoate (3,4-DHB) before sepsis. "
4.	Hypoxia (Hypoxemia) 04/15/2005 - "The purified recombinant enzyme (P4H1) was dependent on physiological concentrations of O(2), alpha-ketoglutarate, and ascorbate and was inhibited by CoCl(2), 3,4-dihydroxybenzoate, and 3,4-dihydroxyphenyl acetate, as observed for known animal cytoplasmic P4Hs of the hypoxia-inducible factor-alpha (HIFalpha) class. "

Related Drugs and Biologics

1.	Prolyl Hydroxylases (Prolyl Hydroxylase)
2.	Glutathione Disulfide (GSSG)
3.	Hydroxyl Radical
4.	Nitric Oxide (Nitrogen Monoxide)
5.	L-Lactate Dehydrogenase (Lactate Dehydrogenase)
6.	Ketoglutaric Acids (Ketoglutaric Acid)
7.	Glutathione (Reduced Glutathione)
8.	Enzymes
9.	Acetylcysteine (Siran)
10.	Acetates (Acetic Acid Esters)